Pfizer reported topline Phase II results for tilrekimig, a trispecific antibody targeting IL‑4, IL‑13, and TSLP for atopic dermatitis. The company said the study met its primary endpoint with a placebo-adjusted improvement in EASI‑75 at week 16 and announced plans to advance a broader clinical development program. Tilrekimig is being evaluated as a once-monthly subcutaneous option for patients with type 2 inflammatory disease, and Pfizer’s statement positions the combination of cytokine pathway inhibition and TSLP modulation as a route to improved efficacy versus standard of care. Next milestones will include continued Phase II development stages and later Phase III execution as Pfizer seeks to validate whether the early efficacy profile translates into durable disease control and clinically meaningful differentiation.